WiseGuyReports have announced the addition of a new report titled “2019 Global and Regional Hormone Refractory Breast Cancer Market Research Report Forecast 2025”.
Breast cancer is the most common cancer that affects the women of the developed as well as the developing countries. The hormone-refractory breast cancer market is growing owing to the increase in the number of hormone therapies. Hormone refractory breast cancer refers to the growing resistance of breast cancer towards hormone therapy due to its continuous use. The increase in the aging population and the growth in the number of individuals affected by breast cancer further accelerate the growth.
The increase in the incidence of hormone-refractory breast cancer and the increase in the availability of anti-cancer pipeline drugs are some of the important factors responsible for market growth. The global hormone-refractory breast cancer market is estimated to witness significant growth during the forecast period.
An increasing number of hormone therapies have made refractory breast cancer resistant to treatment, increased incidence of breast cancer, aging population, increased demand for advanced therapies, increased incidence of hormone-refractory breast cancer and the existence of a large number of anti-cancer pipeline drugs, all of which drive the growth of hormone-refractory breast cancer market.
Key Market Drivers and Restraints
The increase in the incidence of breast cancer across the globe is a key driving factor of the global hormone-refractory breast cancer market. The increase in the investments for research and development of breast cancer drugs and the rise in demand for advanced therapeutics are some other factors that contribute towards the growth of the market. The growth in urbanization and the increasing in the adoption of western lifestyle also boost the market growth.
The social stigma associated with the examination of breast cancer is a key restraining factor that hampers the growth of the market. The lack of advanced chemotherapeutic treatments is another obstacle that limits the market growth.
The global hormone-refractory breast cancer market is classified based on type, application, and geographical regions.
Depending on the type, the global market is divided into tumor markers therapy, gene mutation therapy, and gene expression therapy.
Based on the application, the hormone-refractory breast cancer market is segmented into scientific research and production, medical technology, biological science and technology, and medical apparatus and instruments.
Based on the geographical regions, the global market of hormone-refractory breast cancer includes North America, India, Europe, Southeast Asia, Central, and South America, Japan, and China. North America is the leading region of the global hormone-refractory breast cancer market. Europe region occupies the second position in the global market. The increase in the number of breast cancer patients and the growing geriatric population in both the regions accounts for the leading positions. The presence of drug developers and increase in the drug development activities in the regions will further boost the market growth. Asia Pacific region will witness rapid growth during the forecast period.
The significant players in the global market are AmpliMed Corporation, Sanofi Genzyme, Neopharm, Bluefish Pharmaceuticals AB, Roche, AstraZeneca, NeoCorp, and Boehringer Ingelheim GmbH.
For more information or any query mail at [email protected]
Wise Guy Reports are a part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the global.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)